Brief: Tiziana Life Sciences Announces Additional Clinical Improvements
03/01/2023 13:19
Jan 3 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES ADDITIONAL CLINICAL
IMPROVEMENTS
IN THE SECOND PATIENT WITH NON-ACTIVE SECONDARY PROGRESSIVE
MULTIPLE SCLEROSIS (SPMS) AFTER ELEVEN MONTHS OF DOSING WITH
INTRANASAL FORALUMAB
Source text for Eikon: ID:nGNXbKCtyt
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis